Arcturus Therapeutics Holdings Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Arcturus Therapeutics Holdings Inc 's ROA in the second quarter of 2026?
Arcturus Therapeutics Holdings Inc recorded a cumulative net loss of $-93 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -36.46%.

However, within the Healthcare sector 467 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3614, from total ROA ranking in the first quarter of 2026 at 4103.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-27.47 %	-26.03 %	-14.06 %	-17.24 %	-13.66 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-93	-79	-66	-67	-60
Return On Assets (TTM)	-36.46 %	-28.4 %	-22.03 %	-21.54 %	-18.54 %
ARCT's Total Ranking	# 3614	# 4103	# 3567	# 3524	# 3597
Total Assets (TTM) in million	224	245	271	282	309
Seq. Total Assets Change	-8.6 %	-9.49 %	-3.97 %	-8.71 %	-6.79 %
Seq. Net Income Change	-	-	-	-	-

ARCT's 5 Years Annual ROA >> Back to ARCT Management Effectiveness >> Compare ARCT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 185
Sector	# 468
Overall	# 3717

Return On Assets Statistics
High	Average	Low
28.68 %	-26.34 %	-68.14 %
(Mar 31 2023)		(Sep 30 2018)

News about Arcturus Therapeutics Holdings Inc Return on Assets ROA

Groundbreaking Study Shows Enhanced Immunogenicity of Self-Amplifying mRNA COVID-19 Vaccine Compared to Conventional ...

In a pivotal development within the COVID-19 vaccination landscape, CSL (ASX: CSL; USOTC: CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) have unveiled results from a head-to-head clinical trial that highlights the superior immunogenicity of a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine over the conventional mRNA vaccine, Comirnaty, even at the one-year mark post-vaccination. This groundbreaking study provides compelling evidence suggesting that the sa-mRNA vaccine, which requires only one-sixth of the dose of its traditional counterpart, may represent a more effective approach to managing COVID-19, particularly as new variants continue to emerge.The clinical trial compared the immune responses elicited by the sa-mRNA vaccine against those produced by Comirnaty, revealing that the novel vaccine maintained robust immunogenicity not only against the original Wuhan-Hu-1 strain but also against significant variants, including the Omicron BA.4-5 lineages. These findings underscore the potential of self-amplifying technology to not only enhance immunity but also to reduce the volume of vaccine required per dose, making it a potentially more efficient solution for global vaccination efforts.

Financial Statements
Arcturus Therapeutics Holdings Inc 's Assets	$ 224 million	ARCT's Balance sheet
Arcturus Therapeutics Holdings Inc 's Income	$ -24 million	Quarterly ARCT's Income Statement
ARCT's Income by Division		See ARCT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-21.34 %	-20.93 %	-4.02 %	7.95 %	-31.63 %
Total Assets in million	248	316	399	416	385
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-66	-81	-30	9	-204
Annual Return On Assets	-26.51 %	-25.65 %	-7.45 %	2.25 %	-52.89 %

ARCT's 5 Years Annual ROA >> Back to ARCT Management Effectiveness >> Compare ARCT ROA to its Competitors

More Return On Assets Ratios
ARCT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ARCT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ARCT's Competitors
Subscribers only: Roa for Arcturus Therapeutics Holdings Inc 's Suppliers
Subscribers only: Return On Assets for ARCT's Customers

You may also want to know
ARCT's Roi	ARCT's Inventory Turnover Ratio	ARCT's Growth Rates	ARCT's Dividend Comparisons
	ARCT's Profitability Ratios	ARCT's Asset Turnover Ratio	ARCT's Dividend Growth
ARCT's Roe	ARCT's Valuation Ratios	ARCT's Financial Strength Ratios	ARCT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T01:08:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.